Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) is anticipated to post its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Lexeo Therapeutics to post earnings of ($0.32) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 24, 2026 at 9:30 AM ET.

Lexeo Therapeutics Stock Down 2.4%

NASDAQ:LXEO opened at $5.65 on Friday. The firm’s fifty day simple moving average is $6.97 and its 200 day simple moving average is $7.90. The stock has a market cap of $412.38 million, a P/E ratio of -2.09 and a beta of 1.78. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $10.99.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 10,173 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total value of $64,903.74. Following the sale, the chief executive officer owned 392,483 shares in the company, valued at approximately $2,504,041.54. This represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LXEO. AQR Capital Management LLC grew its position in Lexeo Therapeutics by 370.0% in the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after purchasing an additional 39,627 shares during the period. Millennium Management LLC lifted its holdings in shares of Lexeo Therapeutics by 654.8% during the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock valued at $3,718,000 after buying an additional 929,538 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Lexeo Therapeutics in the 1st quarter worth $85,000. Rhumbline Advisers grew its holdings in shares of Lexeo Therapeutics by 19.8% in the first quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after acquiring an additional 4,995 shares during the period. Finally, Cerity Partners LLC bought a new stake in shares of Lexeo Therapeutics in the second quarter worth $50,000. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on LXEO shares. Raymond James Financial assumed coverage on shares of Lexeo Therapeutics in a research note on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 target price on the stock. Chardan Capital reissued a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, January 13th. Cantor Fitzgerald began coverage on Lexeo Therapeutics in a research report on Monday, December 1st. They set an “overweight” rating and a $19.00 price objective on the stock. HC Wainwright reduced their target price on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Finally, Oppenheimer restated an “outperform” rating and issued a $20.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.00.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.